Your browser doesn't support javascript.
loading
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf, E A; Ardavanis, A; Symanowski, J; Murray, J L; Shumway, N M; Litton, J K; Hale, D F; Perez, S A; Anastasopoulou, E A; Pistamaltzian, N F; Ponniah, S; Baxevanis, C N; von Hofe, E; Papamichail, M; Peoples, G E.
Afiliación
  • Mittendorf EA; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA eamitten@mdanderson.org.
  • Ardavanis A; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte.
  • Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Shumway NM; Department of Hematology/Oncology, Brooke Army Medical Center, Ft Sam Houston Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
  • Hale DF; Department of Surgery, Brooke Army Medical Center, Ft Sam Houston.
  • Perez SA; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • Anastasopoulou EA; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • Pistamaltzian NF; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • Ponniah S; Cancer Vaccine Development Laboratory, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda.
  • Baxevanis CN; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • von Hofe E; Antigen Express, Worcester.
  • Papamichail M; Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece.
  • Peoples GE; Cancer Vaccine Development Program, San Antonio Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, USA.
Ann Oncol ; 27(7): 1241-8, 2016 07.
Article en En | MEDLINE | ID: mdl-27029708
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Vacunas contra el Cáncer / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor ErbB-2 / Vacunas contra el Cáncer / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido